Filing Flows › BridgeBio Pharma (BBIO) › Q2 2026 › vs Q1 2026
BridgeBio Pharma (BBIO) Q2 2026 vs Q1 2026 (quarter over quarter)
BridgeBio Pharma's revenue rose $49.2M (+25%) from $195M in Q1 2026 to $244M in Q2 2026. The biggest changes: Net product revenue +$41.8M (+23%); Royalty revenue +$5.9M (+62%); License and services revenue +$1.4M (+31%).
BridgeBio Pharma, Q2 2026: revenue $244M (+120% year over year), operating margin -43.9%, net loss $156M, operating cash flow −$71.1M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Net product revenue | $222M | $181M | $41.8M | +23% |
| Royalty revenue | $15.4M | $9.5M | $5.9M | +62% |
| License and services revenue | $5.8M | $4.4M | $1.4M | +31% |
| Revenue | $244M | $195M | $49.2M | +25% |
| Net loss | $156M | $167M | −$10.7M | -6% |
| Costs & expenses | $400M | $361M | $38.5M | +11% |
| Operating costs | $351M | $300M | $50.3M | +17% |
| Interest & other, net | $48.8M | $60.6M | −$11.8M | -19% |
| Cost of revenue | $15.0M | $9.9M | $5.1M | +51% |
| Research & development | $149M | $127M | $22.8M | +18% |
| SG&A | $186M | $164M | $22.4M | +14% |
| Operating cash sources | $156M | $167M | −$10.7M | -6% |
| Depreciation & amortization | $1.1M | $1.2M | −$133K | -11% |
| Share-based compensation | $44.1M | $33.2M | $10.8M | +33% |
| Working capital & other | $39.7M | −$65.2M | $105M | — |
| Cash used in operations | $71.1M | $197M | −$126M | -64% |
| Net loss absorbed | $156M | $167M | −$10.7M | -6% |
Questions
How much did BridgeBio Pharma's revenue grow quarter over quarter in Q2 2026?
BridgeBio Pharma's revenue rose $49.2M (+25%) from $195M in Q1 2026 to $244M in Q2 2026.
What drove BridgeBio Pharma's revenue change in Q2 2026?
Net product revenue +$41.8M (+23%); Royalty revenue +$5.9M (+62%); License and services revenue +$1.4M (+31%).